Form 4: Evolent Health President Daniel McCarthy Executes Stock Options and Sells Shares Under 10b5-1 Plan

Daniel McCarthy, President of Evolent Health, exercised stock options and sold shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Summary

• Daniel Joseph McCarthy, President of Evolent Health, Inc., executed a series of transactions involving the company's Class A Common Stock.
• On August 22, 2024, McCarthy exercised options to purchase 4,550 shares at $24.75 per share.
• McCarthy then sold 16,693 shares at $30, 7,000 shares at $33 on August 22, 2024.
• On August 23, 2024, McCarthy sold 6,469 shares at $32 and 4,000 shares at $33.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on March 1, 2024.
• Following these transactions, McCarthy directly owns 188,340 shares of Class A Common Stock, which includes restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy and do not necessarily indicate a change in the executive's confidence in the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, although the 10b5-1 plan mitigates this concern.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Insider transactions are common and closely monitored in the healthcare technology industry. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Comparing McCarthy's transactions to other executives in similar healthcare technology companies, the use of a 10b5-1 plan is a common practice.
• Companies like Teladoc Health and Cerner (now Oracle Health) also see regular insider trading activity, often under similar pre-arranged plans.
• The volume of shares traded is within a normal range for executive transactions in companies of Evolent Health's size.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market, but the 10b5-1 plan should mitigate any significant concerns.

Key Dates